WallStSmart

IQVIA Holdings Inc (IQV)vsRLX Technology Inc (RLX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

IQVIA Holdings Inc generates 351% more annual revenue ($16.31B vs $3.62B). RLX leads profitability with a 25.5% profit margin vs 8.3%. IQV trades at a lower P/E of 21.2x. IQV earns a higher WallStSmart Score of 72/100 (B).

IQV

Strong Buy

72

out of 100

Grade: B

Growth: 6.0Profit: 7.0Value: 10.0Quality: 4.3
Piotroski: 4/9Altman Z: 1.33

RLX

Strong Buy

68

out of 100

Grade: B-

Growth: 7.3Profit: 6.0Value: 8.3Quality: 7.8
Piotroski: 5/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

IQVUndervalued (+49.1%)

Margin of Safety

+49.1%

Fair Value

$348.46

Current Price

$165.64

$182.82 discount

UndervaluedFair: $348.46Overvalued
RLXUndervalued (+47.9%)

Margin of Safety

+47.9%

Fair Value

$4.68

Current Price

$2.21

$2.47 discount

UndervaluedFair: $4.68Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

IQV3 strengths · Avg: 8.3/10
Return on EquityProfitability
21.4%9/10

Every $100 of equity generates 21 in profit

PEG RatioValuation
0.978/10

Growing faster than its price suggests

EPS GrowthGrowth
23.6%8/10

Earnings expanding 23.6% YoY

RLX5 strengths · Avg: 9.8/10
Price/BookValuation
1.2x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
46.8%10/10

Revenue surging 46.8% year-over-year

EPS GrowthGrowth
81.9%10/10

Earnings expanding 81.9% YoY

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Profit MarginProfitability
25.5%9/10

Keeps 26 of every $100 in revenue as profit

Areas to Watch

IQV1 concerns · Avg: 2.0/10
Altman Z-ScoreHealth
1.332/10

Distress zone — elevated risk

RLX1 concerns · Avg: 3.0/10
Return on EquityProfitability
5.9%3/10

ROE of 5.9% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : IQV

The strongest argument for IQV centers on Return on Equity, PEG Ratio, EPS Growth. Revenue growth of 10.3% demonstrates continued momentum. PEG of 0.97 suggests the stock is reasonably priced for its growth.

Bull Case : RLX

The strongest argument for RLX centers on Price/Book, Revenue Growth, EPS Growth. Profitability is solid with margins at 25.5% and operating margin at 11.0%. Revenue growth of 46.8% demonstrates continued momentum.

Bear Case : IQV

The primary concerns for IQV are Altman Z-Score.

Bear Case : RLX

The primary concerns for RLX are Return on Equity.

Key Dynamics to Monitor

IQV profiles as a value stock while RLX is a growth play — different risk/reward profiles.

IQV carries more volatility with a beta of 1.41 — expect wider price swings.

RLX is growing revenue faster at 46.8% — sustainability is the question.

IQV generates stronger free cash flow (561M), providing more financial flexibility.

Bottom Line

IQV scores higher overall (72/100 vs 68/100) and 10.3% revenue growth. RLX offers better value entry with a 47.9% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

IQVIA Holdings Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.

RLX Technology Inc

CONSUMER DEFENSIVE · TOBACCO · China

RLX Technology Inc., researches, develops, manufactures, distributes and sells e-vapor products in the People's Republic of China. The company is headquartered in Beijing, China.

Visit Website →

Want to dig deeper into these stocks?